Orally active fluoropyrimidine. Prodrug of doxifluridine, q.v., designed to be metabolized to 5-fluorouracil, q.v., at the tumor site. Prepn: M. Arasaki et al., EP 602454; eidem, US 5472949 (1994, 1995 both to Hoffmann-La Roche). Metabolism by tumor enzymes: T. Ishikawa et al., Cancer Res. 58, 685 (1998). Clinical comparison with i.v. fluorouracil in colorectal cancer: P. M. Hoff et al., J. Clin. Oncol. 19, 2282 (2001); E. Van Cutsem et al., ibid. 4097. Review of pharmacology and clinical experience: J. McKendrick, J. Coutsouvelis, Expert Opin. Pharmacother. 6, 1231-1239 (2005).
Antineoplastic.
Antineoplastic; Antimetabolites; Pyrimidine Analogs